Centers for Disease Control and Prevention (CDC). Addition of history of intussusception as a contraindication for rotavirus vaccination.
MMWR Morb Mortal Wkly Rep. 2011;60:1427.
Ciarlet M, Schodel F. Development of a rotavirus vaccine: clinical safety,
immunogenicity, and efficacy of the pentavalent rotavirus vaccine, RotaTeq.
Desai SN, Esposito DB, et al. Effectiveness of
rotavirus vaccine in preventing hospitalization due to rotavirus gastroenteritis
in young children in Connecticut, USA.
Rotavirus. Centers for Disease Control and Prevention website. Available at:
http://www.cdc.gov/rotavirus. Updated April 11, 2011. Accessed June 5, 2013.
4/14/2009 DynaMed's Systematic Literature Surveillance
https://dynamed.ebscohost.com/about/about-us: Haber P, Patel M, Izurieta HS, et al. Postlicensure monitoring of intussusception after RotaTeq vaccination in the United States, February 1, 2006, to September 25, 2007.
10/30/2009 DynaMed's Systematic Literature Surveillance
https://dynamed.ebscohost.com/about/about-us: Centers for Disease Control and Prevention. Reduction in rotavirus after vaccine introduction—United States, 2000-2009.
MMWR Morb Mortal Wkly Rep.
3/16/2012 DynaMed's Systematic Literature Surveillance
https://dynamed.ebscohost.com/about/about-us: Shui IM, Baggs J, Patel M, et al. Risk of intussusception following administration of a pentavalent rotavirus vaccine in US infants.